Abstract
Kyowa currently ranks 42nd of all researched-based companies in terms of
pharmaceutical sales. This report provides a full review of the company's
activities together with sales forecasts for key products to 2010.
Kyowa has terminated, in March 2005, its Japanese marketing agreement with
Janssen (J&J) for the oral antifungal, Itrizole (itraconazole). The move
leaves Kyowa with just three key products. The loss of Itrizole gives Kyowa a
huge short term headache as it accounted for 19.1% of total pharmaceutical
sales in fiscal 2005.
The company is concentrating its core business in pharmaceuticals and has
divested or restructured many of its non core food and chemical interests.
R&D Pipeline Overview
Kyowa has highlighted three candidate drugs as potential growth drivers for
the future:
- KW-6002 is a novel compound that is indicated for Parkinson's
disease. It is currently being developed in Europe, Canada and the US where it
is anticipated to be filed in 2006.
- KW-7158 differs from existing anticholinergic drugs in that it is
effective on peripheral sensory nerves in the bladder. The development of
KW-7158 indicates a move into a new therapeutic area for Kyowa, urology, with
the company citing the large market potential for this field, both
domestically and abroad.
- KW-2871 is a monoclonal antibody in early-stage development. It has
been shown to be effective against melanoma cells. The company is optimistic
for this compound and is investing in its overseas development.
Major Products Forecast to 2010
- Coniel (Cardiovascular)
- Allelock (Anti-allergenic)
- Celtect (Anti-allergenic)
- Durotep (CNS)
- Depakene (CNS)
- Adriacin/Farmorubicin (Anticancer)
- 5-FU (Anticancer)
- Nauzelin (Gastrointestinal)
- Neu-up (Blood & Fluid)
Table of Contents
LATEST RESULTS
EXECUTIVE SUMMARY
- INTRODUCTION
- FINANCIAL PERFORMANCE 2005
- Sales and market position
- Income
- Sales, Costs and Operating Income
- Expenditure
- Capital expenditure
- Capital Expenditure By Business Area
- Capital Expenditure By Business Area, 2005
- R&D expenditure
- R&D Expenditure and Capital Expenditure
- Divisional performance
- Sales By Business Area
- Sales By Business Area
- Operating Income (Loss) By Business Area
- Total Assets By Business Area
- Geographic performance
- Sales By Destination
- Sales By Destination
- Overseas Sales By Region, 2005
- COMPANY STRATEGY
- Eighth Medium-Term Management Plan
- Financial targets (consolidated)
- Mergers, acquisitions and divestitures
- Key agreements
- Production
- Employees
- Employees and Productivity
- PRODUCT / R&D OVERVIEW
- Key products
- Recent Product Launches
- Recent Product Approvals
- R&D strategy
- R&D pipeline overview
- Sales forecast
- Sales of current top ten products (2000A-2010E)
- CONCLUSIONS
PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT
- Major Products, Therapeutic Areas and Sales
- Sales of Major Pharmaceutical Products, 2005
- R&D Pipeline - Japan
- R&D Pipeline - Overseas
- ANTI-INFECTIVE PRODUCTS
- ANTI-INFECTIVE SUMMARY
- CARDIOVASCULAR PRODUCTS
- Major launched products
- Coniel
- Sales
- Key markets/indications
- Competitor products
- Sales forecast
- Coniel sales (2000A-2010E)
- Activacin
- Others
- CARDIOVASCULAR SUMMARY
- Growth potential
- Limiting factors
- ANTI-ALLERGY PRODUCTS
- Major launched products
- Allelock
- Sales
- Key markets/indications
- Further development
- Competitor products
- Sales forecast
- Allelock sales (2000A-2010E)
- Celtect
- Sales
- Key markets/indications/formulations
- Competitor products
- Sales forecast
- Celtect sales (2000A-2010E)
- ANTI-ALLERGY SUMMARY
- Growth potential
- Limiting factors
- CENTRAL NERVOUS SYSTEM PRODUCTS
- Durotep
- Sales
- Key markets/indications/formulations
- Competitor products
- Sales forecast
- Durotep sales (2000A-2010E)
- Depakene
- Sales
- Key markets/indications/formulations
- Competitor products
- Sales forecast
- Depakene sales (2000A-2010E)
- Others
- CENTRAL NERVOUS SYSTEM R&D
- Topiramate (KW-6485)
- Istradeylline (KW-6002)
- KW-2246
- CENTRAL NERVOUS SYSTEM SUMMARY
- Growth potential
- Limiting factors
- ANTICANCER PRODUCTS
- Adriacin/Farmorubicin
- Sales
- Key markets/indications/formulations
- Sales forecast
- Adriacin/Farmorubicin sales (2000A-2010E)
- 5-FU
- 5-FU sales (2000A-2010E)
- Navelbine
- Others
- ANTICANCER R&D
- KW-2401 (UCN-01)
- Lestaurtinib (KT5555)
- KW-2871
- FGF8
- ANTICANCER SUMMARY
- Growth potential
- Limiting factors
- GASTROINTESTINAL PRODUCTS
- Major launched products
- Nauzelin
- Nauzelin sales (2000A-2010E)
- Acenalin
- Navoban
- Others
- GASTROINTESTINAL SUMMARY
- BLOOD AND FLUID DISORDER PRODUCTS
- Major launched products
- Neu-up
- Sales
- Key markets/indications/formulations
- Competitor products
- Sales forecast
- Neu-up sales (2000A-2010E)
- Leukoprol
- BLOOD AND FLUID DISORDER SUMMARY
- OTHERS PRODUCTS
- OTHERS R&D
- Potelligent technology
- MM-Q01
- KW-3902
- KW-7158
APPENDIX 1 - FINANCIAL PERFORMANCE
- FULL YEAR RESULTS 2005
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
APPENDIX 2 - KEY CORPORATE EVENTS
APPENDIX 3 - KEY AGREEMENTS
- Astellas Pharma Inc
- BioGenex
- Biogen Idec Inc
- BioWa
- 22nd March 2005
- 21st October 2005
- Cephalon Inc
- Signal transduction modulators agreement
- 15th May 1992
- Compugen Ltd
- Eli Lilly
- Eurand SpA
- Genomatica Inc
- Medarex Inc
- MedImmune Inc
- Mitsubishi Pharma Corporation
- NovaCardia Inc
- OncoTherapy Science Inc (OTS)
- Orexo Pharmaceuticals AB
- Sigma Company Limited
- Taisho Pharmaceutical Co Ltd
- Others
- Discontinued Agreements
- Johnson & Johnson
- Geron Corporation
APPENDIX 4 - INFRASTRUCTURE
- RESEARCH AND DEVELOPMENT FACILITIES
- MANUFACTURING FACILITIES
APPENDIX 5 - MAJOR PHARMACEUTICAL SUBSIDIARIES/JOINT VENTURES
- SUBSIDIARIES
- JOINT-VENTURE COMPANIES
APPENDIX 6 - PRODUCT INDEX
|
